Amyloidosis Center News
A Clinician’s Call to Greater ATTR-CM Awareness & Early Diagnosis: A Talk with Tracy Joshi, DNP
ATTR-CM Awareness & Early Diagnosis
STATEMENT ON AMYLOIDOSIS
BY ANN D. PEEL, PRIVATE CITIZEN, BETHESDA, MARYLAND SUBCOMMITTEE ON LABOR, HEALTH AND HUMAN SERVICES, EDUCATION AND RELATED AGENCIES COMMITTEE ON APPROPRIATIONS UNITED STATES SENATE JUNE 4, 2025 DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH. Madam Chairwoman. Amyloidosis is a rare and usually fatal disease. There is no known cure for amyloidosis, an abnormal folding... More
Amyloidosis Genetic Counseling: A Talk with Lucas Pereira
Amyloidosis Genetic Counseling - What You Need to Know
FarmFest 2025
Join us for the 4th annual FarmFest on Saturday, August 9th at Highland Homestead in Pawcatuck, CT! FarmFest 2025 is dedicating proceeds from this year’s music festival to the BU Chobanian & Avedisian School of Medicine Amyloidosis Center. Enjoy a day of community on the farm with all-day local music... More
Vaishali Sanchorawala, MD reviews the clinical challenges and intricacies of care associated with the management of light chain amyloidosis at ASH24.
https://medicaldigest.org/scientific-contents/interview:unraveling-data-and-care-strategies-al-amyloidosis
66th Annual Meeting of American Society of Hematology
Dr Sanchorawala discusses new research presented at the 66th Annual Meeting of American Society of Hematology in San Diego, CA in December 2024. https://www.vjhemonc.com/event/amyloidosis-sessions-highlights-from-ash-2024/
In Memoriam: Dr. Lawreen Connors
October 20, 2024 It is with profound sadness that we announce the passing of our dear colleague, Dr. Lawreen Connors, on October 20, 2024. Lawreen was a cornerstone of the Amyloidosis Center for many years, renowned not only for her groundbreaking research but also for her generosity, mentorship, and collaborative spirit. More
New study underway in Boston for people with advanced stage of AL amyloidosis
Few treatment options exist for patients with this life-threatening rare disease. New research is trying to change that.
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
The HELIOS B trial, recently published in NEJM, has unveiled promising results for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran, a cutting-edge siRNA therapy, significantly reduced the risk of death and cardiac events compared to placebo. Over 36 months, Vutrisiran also showed improvements in walking distance and quality of... More
ISA 2024 Report
Click here to view a synopsis of the BU Amyloidosis Center's attendance at the International Symposium on Amyloidosis at the Mayo Clinic May 26-30, 2024.